摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-methyl-6-(1H-pyrazol-4-yl)pyrazine

中文名称
——
中文别名
——
英文名称
2-methyl-6-(1H-pyrazol-4-yl)pyrazine
英文别名
——
2-methyl-6-(1H-pyrazol-4-yl)pyrazine化学式
CAS
——
化学式
C8H8N4
mdl
——
分子量
160.178
InChiKey
BNGDLHHKLYNRKR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    54.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE
    申请人:Ng Simon C.
    公开号:US20100130490A1
    公开(公告)日:2010-05-27
    Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.
    本发明公开了苯并噁唑和苯并噻唑化合物及其氧化物、酯、前药、溶剂化物和药学上可接受的盐。本发明还公开了该化合物的组合物,其可以单独使用或与至少一种额外治疗剂联合使用,并与药学上可接受的载体一起使用。该实施例可用于抑制细胞增殖,抑制肿瘤的生长和/或代谢,治疗或预防癌症,治疗或预防退变性骨疾病,如类风湿性关节炎,并/或抑制分子,如CSF 1R。
  • CSF-1R, Inhibitors, Compositions, and Methods of Use
    申请人:Sutton James
    公开号:US20100261679A1
    公开(公告)日:2010-10-14
    Disclosed herein are compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof, compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.
    本文公开了化合物及其氧化物、酯、前药、溶剂化物和其药学上可接受的盐,以及化合物的组合物,可以单独使用或与至少一种其他治疗剂合用,并与药学上可接受的载体一起使用,以及化合物的用途,可以单独使用或与至少一种其他治疗剂合用。这些实施例可用于抑制细胞增殖,抑制肿瘤的生长和/或代谢,治疗或预防癌症,治疗或预防类风湿性关节炎等骨骼退化性疾病,并/或抑制分子如CSF-1R。
  • GCN2 inhibitors and uses thereof
    申请人:Merck Patent GmbH
    公开号:US10988477B2
    公开(公告)日:2021-04-27
    The present invention provides compounds inhibiting General amino acid Control Non-derepressible 2 kinase (“GCN2”), compositions thereof, and methods of using the same for treating various disorders, such as cancer.
    本发明提供了抑制通用氨基酸控制非去势 2 激酶("GCN2")的化合物、其组合物及其用于治疗各种疾病(如癌症)的方法。
  • GCN2 INHIBITORS AND USES THEREOF
    申请人:Merck Patent GmbH
    公开号:EP3746075A1
    公开(公告)日:2020-12-09
  • [EN] GCN2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GCN2 ET LEURS UTILISATIONS
    申请人:MERCK PATENT GMBH
    公开号:WO2019148132A1
    公开(公告)日:2019-08-01
    The present invention provides compounds, compositions thereof, and methods of using the same.
    本发明提供了化合物、其组合物以及使用它们的方法。
查看更多